Saturday, May 14, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Remdesivir shows no significant effect on patients with COVID-19 in Solidarity trial

by Medical Finance
in Coronavirus
Study: Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Image Credit: ker_vii / Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Even as the coronavirus disease 2019 (COVID-19) continues to cause thousands of new cases and dozens of deaths each day, research findings highlight the inadequacy of most current drug approaches to treating this potentially deadly condition. A recent study published in the journal The Lancet summarized the final results of the Solidarity trial which aimed at finding out which drugs were most effective at reducing the severity of the disease among hospitalized patients.

Study: Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Image Credit: ker_vii / ShutterstockStudy: Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Image Credit: ker_vii / Shutterstock

Introduction

The Solidarity trial aimed to discover the efficacy of several different therapies used in patients hospitalized with COVID-19.

All patients in the trial had a diagnosis of COVID-19 made by their physicians and received whichever of four drugs were available locally at the time of their entry into the trial – lopinavir, hydroxychloroquine, the interferon IFN-β1a, or remdesivir – while, in addition, a control group received none of these drugs. Whatever other therapies were locally being given at the time were also used in addition to the study drug or control.

In this arm of the study, patients were randomly assigned to receive remdesivir or control. It covered the period from March 22, 2020, to January 29, 2021, including over 14,000 patients from 35 countries worldwide.

What Did the Study Show?

The study’s findings show that while compliance with either remdesivir or control drug was high in both groups, there was no benefit in terms of reduced mortality from remdesivir. In both groups, the mortality was about 15%.

Among patients who were already on mechanical ventilation, death occurred in 42% of remdesivir recipients vs. 39% of controls. Again, of patients who did not receive mechanical ventilation but were on supplementary oxygen, deaths occurred in 15% of the remdesivir group but 16% of the controls.

With low-risk patients who did not initially require oxygen supplementation, there was a mortality toll of 3% in the remdesivir group and 4% among the controls. If all the patients who did not have to be put on ventilation at admission are considered, the mortality outcomes were 12% vs 14% in the remdesivir and control groups.

Moreover, while 16% of the former eventually required ventilation, this occurred in 16% of the control group. When both death and the need for ventilation at some point are combined to form one outcome, this affected 20% of the remdesivir group vs 23% of controls.

The remdesivir group received daily infusions of the drug for ten days unless they were discharged earlier than this. This protocol prolonged the duration of hospitalization to discharge by one day during the treatment period.

These findings mirrored those found in a meta-analysis of mortality data in all earlier randomized trials of the drug as against no-remdesivir protocols. This indicates that “Remdesivir has no significant effect on patients with COVID-19 who are already being ventilated.” In others, it has a negligible effect in preventing death or the need for ventilation, or both.

What Are the Implications?

The study brought up more evidence about the effects of this drug in treating moderate to severe COVID-19 than its earlier interim findings could supply. However, the trend remains the same – both overall, and in different subgroups, such as those on oxygen, those on ventilation, or others, the use of remdesivir failed to bring about any significant reduction in mortality rates. The value of this additional evidence is in the certainty it provides that the trend is not a statistical artifact, while giving more insight into the effect of the drug on the duration of hospitalization to discharge and the incidence of ventilation after admission, as compared to at the time of admission.

This contradicts the earlier claims by the manufacturer of the drug, based on raw analyses from the earlier ACTT-1 trial that remdesivir saved money spent on healthcare by reducing the hospitalization duration by some days. Even the use of open-label remdesivir failed to do this, thus negating both pharmacological and non-pharmacological, or placebo, effects on the time to discharge except that within the 10-day period required for a full course of the drug, discharge was delayed by one day.

“Delays in the discharge of patients who would be discharged within the first 5 or 10 days does not mean remdesivir has no pharmacological effect on time to fitness for discharge, but any such effect is not large and was outweighed by the non-pharmacological effect of patients remaining in hospital to continue remdesivir infusions.”

This corroborates the findings from other trials, showing that the use of the drug delays discharges within the remdesivir treatment period, but this vanishes once this period is over.

These trials showed that while low-risk patients recovered faster with the drug, those who were on supplemental high-flow oxygen or ventilation were not affected favorably. Since high-risk COVID-19 patients succumb largely to the cytokine storm and related systemic hyper-inflammatory responses rather than to the presence of the virus, it might be expected that remdesivir, which inhibits viral replication, would be relatively ineffective. The principal contributor to the difference in outcome is, in fact, the degree of respiratory distress when the patient is admitted.

Patients who did not require oxygen at admission had a mortality of 3%, compared to 15% in those with oxygen supplementation but not ventilation and 30% in the ventilated group. Thus, the mortality increased ten-fold between cohorts when these entry criteria were applied to the whole set of patients.

However, further examination of all available evidence, including that of other trials, seems to indicate that remdesivir may reduce the severity of disease in non-hospitalized patients or those with mild disease at admission (receiving no oxygen, or low-flow oxygen, at entry). More research will be needed on a larger scale to reduce the scale of uncertainty about the results.

Journal reference:

WHO Solidarity Trial Consortium (2022). Remdesivir and Three Other Drugs for Hospitalized Patients With COVID-19: Final Results Of The WHO Solidarity Randomized Trial And Updated Meta-Analyses. The Lancet. https://doi.org/10.1016/S0140-6736(22)00519-0. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00519-0/fulltext

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Image Credit: nnattalli/Shutterstock

Monoclonal antibodies found to prevent lung inflammation in SARS-CoV-2-Omicron-infected mice

by Medical Finance
May 14, 2022
0

In a recent study posted to the bioRxiv* pre-print server, researchers investigated how monoclonal antibodies (MAbs), S309 and AZD7442, reduced...

Study: Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022. Image Credit: spaxiax/Shutterstock

SARS-CoV-2 mRNA vaccines may prevent COVID-19-associated mechanical ventilation and death

by Medical Finance
May 14, 2022
0

In a recent study published in the Morbidity and Mortality Weekly Report, a team of researchers from the United States...

Recombinant SARS-CoV-2 Delta-Omicron variant identified in the United States

Recombinant SARS-CoV-2 Delta-Omicron variant identified in the United States

by Medical Finance
May 14, 2022
0

In a recent study published on the preprint server bioRxiv*, researchers find that there is likely recombination of genome sequences...

Study: Mortality among hospitalized COVID-19 patients during surges of SARS-CoV-2 alpha (B.1.1.7) and delta (B.1.617.2) variants. Image Credit: UfzBizPhoto / Shutterstock.com

Mortality among hospitalized Iranian COVID-19 patients during Alpha and Delta waves

by Medical Finance
May 14, 2022
0

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV‐2), which is the causal agent of the coronavirus disease 2019 (COVID-19), has...

Study: Rapid screening assays of N501Y and E484K SARS-CoV-2 variants and identification of an emerging N501T variant in France. Image Credit: Salov Evgeniy / Shutterstock.com

Novel screening method detects new N501T SARS-CoV-2 variant

by Medical Finance
May 14, 2022
0

For over two years, the world has been navigating the deadly coronavirus disease 2019 (COVID-19) pandemic, which has been caused...

Study: Detection of COVID-19 dysosmia with paired crushable oderant ampules. Image Credit: Microgen / Shutetrstock.com

Rapid and cheap test for dysosmia in COVID-19

by Medical Finance
May 14, 2022
0

Anosmia is a recognized symptom in coronavirus disease 2019 (COVID-19), though it is not present in many patients. A new...

Next Post
First patient-derived stem cell model developed for studying oculocutaneous albinism

Fully dynamic kinetic model of a living 'minimal cell' offers insight into basic principles of life

Study: Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of Concern. Image Credit: NIAID

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Using bead-based, high throughput panels to improve the quality of T helper cell cytokine profiling
    Using bead-based, high throughput panels to improve the quality of T helper cell cytokine profiling
  • Study: Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19. Image Credit: Vitalii Vodolazskyi/Shutterstock
    Study predicts that different statins exhibit divergent effects on host response to SARS-CoV-2 infection
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply